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Objectives: Carbapenem resistance in Pseudomonas aeruginosa is growing and results from variable
mechanisms. The objectives of the current study were to investigate mechanisms of carbapenem
resistance and genetic relatedness of P. aeruginosa isolates recovered in Dubai hospitals.
Methods: From June 2015 through June 2016, carbapenem-nonsusceptible P. aeruginosa were collected
from 4 hospitals in Dubai, and subjected to antimicrobial susceptibility testing, molecular investigation of
carbapenemases by PCR-sequencing, analysis of outer membrane porin OprD2 and multidrug efﬂux
channel MexAB-OprM levels by qPCR, and ﬁngerprinting by ERIC-PCR.
Results: Out of 1969 P. aeruginosa isolated during the study period, 471 (23.9%) showed reduced
carbapenem susceptibility. Of these, 37 were analyzed and 32% of them produced VIM-type metallo-βlactamases, including VIM-2, VIM-30, VIM-31, and VIM-42, while GES-5 and GES-9 co-existed with VIM
in 5.4% of isolates. Outer membrane impermeability was observed in 73% of isolates and 75.6% displayed
overproduced MexAB-OprM. ERIC-PCR revealed one large clone including most carbapenemaseproducing isolates indicating clonal dissemination.
Conclusion: This is the ﬁrst study on carbapenem-nonsusceptible P. aeruginosa from Dubai, incriminating
VIM production as well as outer membrane permeability and efﬂux systems as resistance mechanisms.
Further studies on carbapenem-nonsusceptible P. aeruginosa in Dubai are warranted for containment of
such health hazard.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
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Introduction
Carbapenems, namely imipenem and meropenem, play a
signiﬁcant role in the treatment of infections caused by
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Pseudomonas aeruginosa (Khuntayaporn et al., 2013). However,
the emergence and spread of carbapenem-nonsusceptible P.
aeruginosa is quite alarming (Queenan and Bush, 2007). To date,
different carbapenem resistance mechanisms have been identiﬁed
in this organism including inducible chromosomal AmpC (Lister
et al., 2009), reduced drug uptake due to mutant or lost outer
membrane porins (OprDs), increased drug efﬂux due to overexpression of efﬂux pumps MexAB-OprM, and genetic acquisition
of carbapenem-hydrolyzing enzymes (Li et al., 2012). More
speciﬁcally, OprD2 is a 45–49 KDa outer membrane protein that

https://doi.org/10.1016/j.ijid.2019.04.027
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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serves as binding site for imipenem (Lister et al., 2009). Its deﬁcient
expression usually leads to basal level of multi-drug resistance,
including imipenem resistance (Naenna et al., 2010). Another
contributor to carbapenem resistance in P. aeruginosa is overexpression of a multi-drug efﬂux pump belonging to resistancenodulation-cell division (RND) family, MexAB-OprM. This pump
contributes signiﬁcantly to intrinsic resistance and displays the
broadest substrate proﬁle among all P. aeruginosa efﬂux pumps. Its
mutational overexpression leads to reduced susceptibility to
ﬂuoroquinolones, macrolides, chloramphenicol, tetracyclines,
and most β-lactams including meropenem but not imipenem
(Oliver et al., 2015; Choudhury et al., 2015). MexAB-OrpM efﬂux
pump overproduction coupled to OprD loss makes the organism
highly resistant not only to imipenem but also to meropenem and
doripenem (Hammami et al., 2009). Although carbapenem
resistance in P. aeruginosa is most likely related to the above
two mechanisms, carbapenemases of Ambler classes A, B, and D
have been described in this organism (Potron et al., 2015). Among
class A, or extended-spectrum-β-lactamases, the ﬁrst GES-type
carbapenemase in P. aeruginosa was GES-2 described in South
Africa (Poirel et al., 2001), followed by GES-5 from China (Wang
et al., 2006), and more recently GES-18 from Belgium (Bebrone
et al., 2013). Less frequent reports describe KPC-producing P.
aeruginosa from USA (Poirel et al., 2010). The main carbapenemases in P. aeruginosa belong to Ambler class B metallo-βlactamases. These include VIM enzymes, the ﬁrst described in P.
aeruginosa being VIM-1 (Lauretti et al., 1999), but the more
prevalent nowadays being VIM-2 (Walsh et al., 2005), and IMP
enzymes, of which about 32 variants were reported in this
organism (Potron et al., 2015). More recently in 2011, NDM was
described in P. aeruginosa isolates from Serbia (Jovcic et al., 2011),
and was recovered later in India, Eygpt and Italy (Potron et al.,
2015). Less common metallo-β-lactamases include SPM, GIM, and
SIM ﬁrst isolated in Brazil, Germany, and Korea respectively (Poirel
et al., 2004; Castanheira et al., 2004; Lee et al., 2005). Additionally,
literature has reported carbapenem-hydrolysing class D (oxacillinases) enzymes in P. aeruginosa including OXA-40 and OXA-198
(Potron et al., 2015). Therefore, it is evident that P. aeruginosa is
genetically equipped with outstanding and variable machinery to
be resistant to carbapenems.
In immunocompromised patients, carbapenem nosusceptible P.
aeruginosa is an important pathogen which causes nosocomial
infections, and it has emerged as a widespread Multi Drug
Resistant (MDR) pathogen which requires antibiotic susceptibility
testing on a regular basis (Biswal et al., 2014). For example, 34.1% P.
aeruginosa isolated from neutropenic patients with hematologic
diseases in China (Zhu et al., 2017) and 18.9% isolated from burn
patients in an Indian survey were resistant to imipenem (Biswal
et al., 2014). Also, in a Turkish survey of P. aeruginosa isolated from
intensive care units, rates of carbapenem resistance were found to
increase when monitored over four years (Alişkan et al., 2008). In
pediatric cancer patients with febrile neutropenia, there was an
alarmingly high resistance pattern of Pseudomonas spp. to
carbapenems, with 50% resistant to imipenem and 25% resistant
to meropenem in a recent survey from Eygpt (Kamel et al., 2018).
As far as Dubai is concerned, and to our knowledge, no previous
reports did deﬁne carbapenem resistance in P. aeruginosa, although
reports from some surrounding countries in the Arabian Gulf
region are available (Al-Agamy et al., 2016; Zowawi et al., 2018). For
example, previous studies reported 15% rates of carbapenem
resistance of P. aeruginosa in Oman (Al-Yaqoubi and Elhag, 2008)
and 41% in Lebanon (Hammoudi Halat et al., 2017). Likewise, other
reports showed existence of other Gram-negative pathogens,
such as Enterobacteriaceae with 4.6% rates of carbapenem
resistance in Dubai (Moubareck et al., 2018), and 1.2% in Lebanon
(Hammoudi Halat et al., 2017), with predominance of blaOXA-48 and

blaNDM, while some studies from Saudi Arabia reported blaVIM-4
(Memish et al., 2015). Carbapenem-nonsusceptible strains of
Acinetobacter baumannii have been also reported from the region
with a prevalence approximating 90% in Lebanon (Hammoudi
et al., 2015), as well as from Saudi Arabia, Qatar, Oman, and
Bahrain, with predominance of blaGES-11, blaOXA-23 and other
Ambler class D carbapenemases (Zowawi et al., 2015). With such
evidence accumulating from surrounding countries, there is a need
to investigate carbapenem resistance in P. aeruginosa from Dubai.
As the second largest Emirate among the seven forming the United
Arab Emirates, Dubai represents a major economic and touristic
pivot of the Gulf region. The commercial status and rapid growth of
Dubai has attracted a large proportion of expats and migrant
workers from various geographical areas and diverse cultures,
making it an appropriate venue for spread of bacterial resistance,
especially in a quite versatile organism like P. aeruginosa. In light of
such assortment, a study of Pseudomonas resistance to carbapenems in Dubai is mandatory. The objectives of the current study
were to investigate involvement of carbapenemases, porin loss or
downregulation, and efﬂux pump overactivity in carbapenem
resistance in nosocomial Pseudomonas isolates from Dubai, and to
analyze clonality of the studied strains.
Materials and methods
Isolates and data collection
Over a one year period, between June 2015 and June 2016, P.
aeruginosa isolates with reduced susceptibility to either imipenem
or meropenem at time of their isolation were collected
from tertiary hospitals in Dubai, including two governmental
(Dubai Hospital, DH, and Rashid Hospital, RH) and two
private hospitals (American Hospital, AH, and Mediclinic City
Hospital, MCH). DH and RH are 625- and 786-bed general
medical/surgical specialized hospitals respectively, and both
operate under the Dubai Health Authority, a government
organization overseeing the health system of Dubai. On the
other hand, AH is a 254-bed, acute care, general medical/surgical
private hospital with a multi-specialty physician group practice.
MCH is a 280-bed private hospital that accommodates patients
with a wide range of health requirements, including specialistfocused treatment in cardiology, radiology, gynaecology, trauma, nuclear medicine, endocrinology, obstetrics, neonatal care
and others. Isolates were delivered to Microbiology
Research Laboratories of Zayed University, Dubai, and to
Microbiology
Laboratory
of
Saint-Joseph
University,
Beirut. Among received isolates, those with conﬁrmed nonsusceptibility to imipenem or meropenem according to CLSI
2017 criteria were included in the study.
Data on patient age, gender and nationality, type of clinical
specimen from which Pseudomonas was recovered and brief
disease information were accessed from patient medical ﬁles.
However, data on chief medical complaints, clinical diagnosis,
antibiotic therapy, travel history, and disease outcome following
hospitalization were insufﬁcient; hence relation of these parameters to carbapenem nonsusceptibility was not addressed within
scope of the current study.
Susceptibility testing
Susceptibility testing to nine antimicrobial agents including
imipenem, meropenem, piperacillin-tazobactam, ceftazidime,
cefepime, amikacin, gentamicin, norﬂoxacin, ciproﬂoxacin, was
done using the VITEK 2 Compact Analyzer. Susceptibility testing to
colistin was done using broth microdilution. Results were
interpreted according to CLSI 2017 criteria. Isolates were

Table 1
Minimum inhibitory concentrations, clones detected by ERIC-PCR, and genotypic proﬁle of carbapenem resistance in studied Pseudomonas aeruginosa isolates.
Isolate
number

Clinical specimen

Minimum inhibitory concentrations

Clone Genotypic proﬁle

Piperacillin/
Tazobactam

Ceftazidime Cefepime Imipenem Meropenem Amikacin Gentamicin Ciproﬂoxacin Norﬂoxacin Colistin

OprD2

MEX

Carbapenemase

Mex+
+
Mex+
+
Mex+
+
Mex+
+
Mex+
Mex+
Mex+
+
Mex+
+
Mex+
+
Neg

VIM-30

Mex+
+
Mex+
+
Mex+
+
Mex+
+
Mex+
+
Neg
Mex+
+
Mex+
+
Mex+
+
Mex+
+
Neg
Mex+
Mex+
+
Mex+
+
Mex+
+
Mex+
+
Mex+
+
Mex+
+
Mex+
+

none

Drain ﬂuid

>128 /4

16

32

>16

>16

>64

>16

2

8

1

1

OprD2-

AH2

Wound exudate

>128/4

>64

32

>16

>64

<2

<1

>4

8

1

1

Neg

AH3

Sputum

32/4

4

4

>16

>16

<2

<1

0.5

2

1

6

OprD2-

AH4

Sputum

<4/4

<1

<1

>16

4

4

4

1

2

1

1

Neg

AH5
AH6
AH7

Sputum
Sputum
Sputum

8/4
32/4
8/4

4
8
4

8
8
8

>16
>16
>16

8
>16
8

<2
32
16

<1
8
>16

1
2
2

4
8
4

0.5
1
1

1
3
1

OprD2OprD2OprD2-

AH8

Urine

<4/4

<1

<1

4

4

<2

<1

<0.25

<0.5

0.5

1

OprD2-

AH9

>128/4

>64

>64

>16

>16

32

8

2

4

1

1

OrpD2-

16/4

4

8

>16

>16

4

4

>4

8

0.5

1

OprD2-

AH11

Broncho-alveolar
lavage
Broncho-alveolar
lavage
Wound exudate

>128/4

>64

>64

>16

>16

>64

8

>4

>16

1

1

OprD2-

AH12

Urine

>128/4

>64

>64

>16

>16

>64

>16

>4

>16

0.5

1

Neg

AH13

Unknown

8/4

4

2

>16

8

<2

<1

<0.25

<0.5

0.5

5

OprD2-

AH14

Unknown

8/4

4

2

>16

8

<2

<1

<0.25

<0.5

0.5

1

OprD2-

DH15

Unknown

>128 /4

>64

>64

>16

>16

>64

>16

>4

>16

0.5

1

Neg

DH16
DH17

Unknown
Respiratory ﬂuid

>128/4
16/4

16
4

8
8

>16
>16

>16
>16

>64
4

>16
4

>4
>4

>16
8

1
0.5

1
3

OprD2Neg

DH18

Blood

32/4

4

4

>16

>16

<2

>16

>4

>16

1

1

OprD2-

DH19

Respiratory ﬂuid

>128/4

>64

16

>16

8

<2

<1

<0.25

<0.5

0.5

1

OprD2-

DH20

Wound exudate

>128/4

>64

>64

>16

>16

>64

>16

>4

>16

0.5

1

Neg

DH21
DH22
DH23

Respiratory ﬂuid
Respiratory ﬂuid
Ear

16/4
17/4
32/4

4
16
4

8
32
8

>16
>16
>16

>16
>16
>16

8
16
<2

8
8
2

0.5
1
1

2
2
2

0.5
1
1

1
1
1

DH24

Urine

>128/4

>64

>64

>16

>16

8

4

<0.25

<0.5

1

1

OprD2OprD2Missing
OprD2
OprD2-

DH25

Respiratory ﬂuid

32/4

8

8

>16

>16

<2

<1

0.5

2

1

1

DH26

Wound

8/4

4

2

>16

4

4

4

<0.25

1

1

7

Missing
OprD2
Neg

DH27

Urine

>128/4

>64

>64

>16

>16

16

<1

>4

>16

1

1

OprD2-

DH28

Respiratory ﬂuid

8/4

2

<1

>16

4

<2

<1

1

2

1

4

OprD2-

DH29

Urine

8/4

4

2

>16

4

<2

<1

<0.25

<0.5

1

1

Neg

AH10

none
none
VIM-31
none
none
VIM-30
none
none
none

none
none
none
none
VIM-42 + GES-5
none
VIM-2
none
VIM-2
VIM-42
none
none
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AH1

none
none
VIM-30
VIM-31
none
none
145

VIM-2

considered multidrug-resistant (MDR) if they were non-susceptible to at least one agent in three or more antimicrobial categories,
extrensively drug resistant (XDR) if they remained susceptible to
agents in two or fewer antimicrobial categories, and pandrug
resistant (PDR) if they were non-susceptible to all agents in all
antimicrobial categories (Magiorakos et al., 2012).
Detection of carbapenemase- and porin-encoding genes

OprD2-

Genomic DNA was extracted from samples by boiling method,
and stored at 20  C. Molecular investigation of carbapenemaseencoding genes was done by PCR-sequencing according to inhouse protocols set by Institut Pasteur, France (Courvalin, 2011), as
well as other previously designed conditions (Queenan and Bush,
2007; Poirel et al., 2011). Investigated genes belonged to Ambler
class A, namely blaGES and blaKPC and Ambler class B, namely blaIMP1, blaIMP-2, blaVIM, blaNDM, blaGIM, blaSIM, and blaSPM. Moreover, the
gene encoding the outer membrane porin OprD2 was investigated
as previously described (El Amin et al., 2005).
Sequencing was performed to identify subtypes of blaGES and
blaVIM genes as discussed previously (Courvalin, 2011).
RNA extraction and real-time PCR

0.5
1 (S)
1 (S)
DH = Dubai Hospital; RH = Rashid Hospital; AH = American Hospital; MCH = Mediclinic City Hospital.
OprD2-: down regulation of OprD2 porin.
Mex++: overexpression of mexB (increase by at least 3-fold).
Mex+: borderline expression of mexB (increase by 2 to 3-fold).
Neg: negative detection of OprD2 downregulation or MexB overexpression by qRT-PCR.

>64
32 (R)
>64 (R)

>16
>16 (R)
>16 (R)

>16
>16 (R)
>16 (R)

>64
<2 (S)
>64 (R)

>16
<1 (S)
>16 (R)

>4
<0.25 (S)
>4 (R)

>16
<0.5 (S)
>16 (R)
32
16 (I)
>64 (R)
>128/4
<4/4 (S)
>128/4 (R)
Sputum
MCH37
MIC50
MIC90

1

none
VIM-2 + GES-9
OprD2OprD21
0.5
>64
>64

>16
>16

>16
8

>64
>64

>16
>16

>4
>4

>16
>16
>64
>64
>128/4
>128/4
Unknown
Foot ulcer
RH35
MCH36

2
1

none
OprD20.5
>64

>16

>16

>64

>16

>4

>16
>64
>128/4
Unknown
RH34

1

none
OprD21
1
4
2

>16

<2

<1

<0.25

<0.5
4
8/4
Wound
DH33

0.5
1
>16
4
8
<1

>16
>16

>64
8

>16
4

>4
<0.25

>16
<0.5
16
2
32/4
<4 /4
Wound
Respiratory ﬂuid
DH31
DH32

1
1

OprD2OprD2-

VIM-2
none

none

Mex+
+
Mex+
Mex+
+
Mex+
+
Mex+
+
Neg
Mex+
+
Neg
1
>16
DH30

>64

>16

>64

>16

>4

>16
>64
>128/4
Blood

1

OprD2-

Carbapenemase
OprD2
Ceftazidime Cefepime Imipenem Meropenem Amikacin Gentamicin Ciproﬂoxacin Norﬂoxacin Colistin
Piperacillin/
Tazobactam

Minimum inhibitory concentrations
Clinical specimen
Isolate
number

Table 1 (Continued)

MEX
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Clone Genotypic proﬁle
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Levels of expression of the genes mexB and oprD2, representing
efﬂux pump MexAB-OprM, and outer membrane protein OprD2
respectively, were determined by quantitative real-time PCR (qRTPCR). Total RNA was extracted and synthesized into cDNA, that was
subjected to qRT-PCR using CFX96 Touch Real-Time PCR Detection
System (Bio-Rad). A gene ecoding a 30S ribosomal protein, rpsL,
was used as house-keeping control gene for normalizing transcription levels of target genes.
For isolation of RNA, isolates were cultivated overnight, diluted
in brain heart infusion broth to logarithmic phase, identiﬁed by
optical density (OD600) of 0.5, then centrifuged. The RNeasy Protect
Bacteria Mini Kit (Qiagen, Hilden, Germany) was used for RNA
extraction from the pellet as per manufacturer recommendations.
RNase-Free DNase (Qiagen, Hilden, Germany) was used to
eliminate contaminating DNA, and cDNA was synthesized with
Omniscript RT Kit (Qiagen, Hilden, Germany). For qRT-PCR,
expression of mexB and oprD2 was performed on cDNA using
QuantiTect SYBR Green RT-PCR kit (Qiagen, Hilden, Germany), and
expression levels were examined and compared to those of rpsL.
The wild-type PAO1 of P. aeruginosa, was used as a positive control.
The assay was performed in triplicate for each sample, using three
independent RNA extractions, and the mean of three obtained
quantities was considered as quantity of given gene expression for
that sample. The DDCt was used for determining gene expression
level, and was calculated by subtracting DCt of sample from that of
reference strain PAO1. The gene mexB was considered upregulated
for an isolate when corresponding mRNA level was at least 3-fold
higher than that of PAO-1 (reported as Mex++), and borderline if
between 2- and 3-fold (reported as Mex+) (Cabot et al., 2011). The
gene oprD2 was considered downregulated when corresponding
mRNA level was at least 2-fold lower than that of PAO-1 (OcampoSosa et al., 2012; Hocquet et al., 2006).
Investigation of clonal relatedness
Analysis of clonality of the studied isolates was performed by
Enterobacterial Repetitive Intergenic Consensus-based PCR (ERICPCR) (Versalovic et al., 1991), using previously described conditions (Ferreira et al., 2011) but with annealing temperature of
58  C. Banding patterns were converted by GelQuest/Sequentix1
(Klein Raden, Germany) software into a binary matrix of either 1 or
zero scores, and used to construct a dendrogram via unweighted
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pair-group method using arithmetic averages (UPGMAs) clustering. The results for ﬁngerprinting were analyzed using Dice
coefﬁcient. Isolates with more than 85% similarity were considered
closely related and, therefore, were treated as clones; these isolates
differed in one to two bands (Syrmis et al., 2004).
Results
Study samples and patients
A total of 1969 P. aeruginosa were isolated by the participating
hospitals during the study period. Of these, 471 were carbapenemnonsusceptible (overall prevalence of 23.9%). Thirty-seven isolates
met the inclusion criteria and were subjected to further analysis.
The largest proportion of samples was from Dubai hospital and
American hospital, contributing with 14 and 19 samples respectively (Table 1). Specimens for recovery of carbapenem nonsusceptible P. aeruginosa included urine, sputum, blood, respiratory samples, ear samples, drain ﬂuid, foot ulcer samples, and wound
exudates. Patients from were from different nationalities including
nine from UAE, four from the nearby countries Kuwait, Saudi
Arabia, Yemen, and Oman, and one from India.
Results of antimicrobial susceptibility testing
The results of antimicrobial susceptibility testing are shown in
Table 1. Sixteen isolates (43%) were resistant to piperacillin/
tazobactam with minimum inhibitory concentrations at which 90%
of isolates were inhibited (MIC90) superior or equal to 128/4 mg/mL.
The MIC90 values of ceftazidime and cefepime were above 64 mg/mL,
indicating high resistance. Thirty isolates (81%) were resistant to both
imipenem and meropenem. Six isolates (AH8, DH26, DH28, DH29,
DH32 and DH33) showed high imipenem resistance but intermediate
resistance to meropenem with imipenem MICs greater than 16 mg/
mL and meropenem MICs equal to 4 mg/mL. One isolate AH8 was both
imipenem and meropenem intermediate with MICs of both
carbapenems equal to 4. Regarding amikacin, gentamicin, ciproﬂoxacin, and levoﬂoxacin, we observed variable sensitivities, but MIC90
values were superior to 64, 16, 4, and 64 mg/mL respectively,
indicating resistant phenotypes. A discrepancy of MIC50s and MIC90s
was noted for the latter agents (Table 1) with MIC50s being susceptible
while MIC90s are resistant, probably indicating that our collection
includes at least two subpopulations with wide variation in their
MICs towards these agents (Schwarz et al., 2010). Four strains (11%)
were MDR, and 14 (38%) were XDR, while none was characterized as
PDR since they retained colistin sensitivity.
Results of carbapenemase and oprD2 genes detection
VIM metallo-β-lactamase was detected in 12 out of the 37
studied isolates (32.43%), and was the most prevalent among
investigated carbapenemases. Sequencing of the VIM-positive
isolates revealed VIM-2, VIM-30, VIM-31, and VIM-42 in 5, 3, 2, and
2 isolates respectively. Next to VIM, we detected the Ambler class A
GES β-lactamase, with one VIM-2-positive isolate co-harboring
GES-9, and one VIM-42-positive isolate co-harboring GES-5. It is
worth noting that among the aforementioned GES enzymes, only
GES-5 is a carbapenemase (Viedma et al., 2009), while GES-9
spares carbapenems (Poirel et al., 2005). The VIM-2 producing
isolates were recovered from two different hospitals, as were those
producing VIM-31; those producing VIM-30 were from the same
hospital, and those producing VIM-42 were from a different one.
Other investigated metallo-β-lactamases and KPC were not
detected. The gene encoding the outer membrane porin gene
oprD2 was detected in 35 out of the 37 isolates and was missing in
DH23 and DH25.

Figure 1. Dendrogram showing results of ﬁngerprinting of the 37 studied isolates
using ERIC-PCR at 85% similarity, with the 7 clones and hospital sources shown.
DH = Dubai Hospital; RH = Rashid Hospital; AH = American Hospital; MCH = Mediclinic City Hospital.

Results of qRT-PCR
Although oprD2 gene was present in all but two of our isolates,
different levels of gene expression were detected by qRT-PCR.
Twenty-seven isolates out of 37 (73%) displayed downregulation of
oprD2 mRNA when compared to level of gene expression of oprD2
in the control strain PAO1 (Table 1). Also, 28 out of 37 isolates
(75.6%) showed overproduction of mexB mRNA, indicating resistance resulting from efﬂux pump overexpression. The expression
of mexB was borderline (2–3 folds higher than the reference strain
PAO1) in 4 isolates, and hence efﬂux mechanism was not
incriminated in their resistance to carbapenems.
Results of genotyping and qRT-PCR interestingly demonstrates
that multiple mechanisms of resistance co-existed in 30 out of 37
of our isolates, with combinations of carbapenemases, OprD2 loss
or downregulation, and/or MexB overexpression. In only seven
studied strains, the detected determinants of resistance were
single (2 isolates with OprD2 downregulation and 5 isolates with
MexB overexpression).
Results of clonality analysis
ERIC-PCR ﬁngerprinting analysis of the 37 isolates revealed 7
clones (Figure 1). Notably, 30 strains (81%) belonged to a single
large clone, and they were recovered from the four participating
hospitals, probably indicating an apparent clonal spread. This clone
included 11 out of the 12 isolates with documented detection of the
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different VIM and GES. The 6 remaining clones were smaller,
including 1 or 2 strains, with a single VIM-30-positive isolate in
clone 7. Deﬁciency of OprD2 gene expression was observed among
5 out of the 7 clones. Clone 3 included two strains where our tested
carbapenemase genes were negative. Only two samples were
recovered from blood culture (DH18 and DH30), and both belonged
to clone 1 and shared downregulation of OprD2 and 3-fold
overexpression of mexB. This clone also included samples from
numerous other sites such as urine, respiratory ﬂuid, and wound
exudate, and its detection in the four hospitals may indicate a
clonal inter-institutional spread.
Discussion
The global perturbing situation of carbapenem resistance in P.
aeruginosa isolates observed in the last decade, together with
obvious lack of reports from the Emirate of Dubai, both unveil need
for a baseline investigation. This study was conducted in four
centers located in Dubai to gain an overview of the status of
susceptibility to carbapenem in P. aeruginosa over a 1-year period.
The prevalence of non-susceptibility to carbapenems for P.
aeruginosa was 23.9%. This prevalence is higher than that reported
for Oman (15%) (Al-Yaqoubi and Elhag, 2008), but lower than that
for Saudi Arabia (52%) (Al-Otaibi et al., 2016), and Lebanon (41%)
(Hammoudi Halat et al., 2017). Concerning level of resistance to
imipenem and meropenem, our data show high MIC50s, superior to
16 mg/mL, for both carbapenems. Resistance to other β-lactams
and other antibiotic classes was variable with few isolates
exhibiting MDR phenotype, and about 40% being XDR. The absence
of PDR isolates warrants follow up for colistin sensitivity status in
Dubai.
To clarify the mechanisms of resistance to carbapenems in our
isolates, carbapenemases were investigated. VIM metallo-βlactamase appears to be the leading carbapenemase in this study.
This carbapenemase has been detected in P. aeruginosa in close
countries such as Lebanon (Hammoudi Halat et al., 2017), Kuwait,
and Egypt (Zafer et al., 2015), with reports of VIM-2 (Kazmierczak
et al., 2016); and Saudi Arabia, with reports of VIM-4 (Al-Agamy
et al., 2016). VIM-31, detected in two studied isolates, is a new,
mutant variant of VIM-2, ﬁrst detected in Enterobacter cloacae
(Bogaerts et al., 2012; Kupper et al., 2015). Interestingly, VIM-31
enzyme has weaker catalytic efﬁciency against β-lactam agents
(Bogaerts et al., 2012), probably explaining low MIC of piperacillintazobactam, ceftazidime, and cefepime, depicted in isolate AH4. On
the other hand, all these MICs substantially rise in isolate DH27, in
which VIM-31 is accompanied with OprD2 downregulation. Two
isolates showed presence of VIM-42, a variant of VIM-1 previously
described in 2013 in Klebsiella pneumoniae from an Italian patient
with urinary tract infection (Kazmierczak et al., 2016). The
diversity of VIM carbapenemases in P. aeruginosa stresses on its
importance as a large reservoir of blaVIM gene cassettes (Sedighi
et al., 2014).
The genetic platform of blaVIM is capable of expression and
acquisition of other genes, and may co-exist with one or more
resistance determinants (Zhao and Hu, 2011). This scenario is
demonstrated in our results, where two VIM-producing isolates
produced either GES-5 or GES-9, both of which are ESBLs. GES-9 is
a variant of GES-1 with broad hydrolysis spectrum for many βlactams, but spares carbapenems and hydrolyzes aztreonam. GES5, detected in isolate DH16, is a carbapenem-hydrolyzing ESBL ﬁrst
described in P. aeruginosa from Turkey (Iraz et al., 2014), and more
recently from Saudi Arabia (Memish et al., 2015). In this latter
report, no GES-5-harboring strains co-produced another carbapenemase, unlike our ﬁndings of GES-5 coexisting with VIM-42. The
existence of GES-type β-lactamases with or without other enzymes

in P. aeruginosa from the area was demonstrated elsewhere (AlAgamy et al., 2016), and stresses the need for further investigation.
GES-5 was earlier detected in far geographic areas, like China
(Wang et al., 2006: 5), South Africa (Labuschagne et al., 2008), and
Brazil (Picão et al., 2009), reﬂecting possibility of inter-country
spread, given diverse nationalities with population ﬂow into
Dubai. We do not know whether such isolates have been recently
transferred through international travel, or whether they existed
since a long time and were not detected in the absence of
surveillance for carbapenem resistant P. aeruginosa.
Genotypic investigation for oprD2 gene by PCR showed its
existence in 35 out of the 37 studied isolates, and a major
proportion (27 isolates) showed downregulation of OprD2 by qRTPCR, conferring decreased carbapenem permeability. This ﬁnding
was demonstrated in another study from the region (Al-Agamy
et al., 2016), and also earlier in P. aeruginosa carbapenem
resistance literature (El Amin et al., 2005; Liu et al., 2013).
Furthermore, OprD2 downregulation was detected in 5 out of 7
clones from different participating hospitals conﬁrming the role of
impermeability as a major contributor to resistance in P.
aeruginosa.
In addition to permeability lesions and carbapenemases, the
majority of our isolates displayed upregulated efﬂux pump activity.
Previous documentation of such resistance mechanism in P.
aeruginosa exists from the Arabian Gulf and elsewhere (Al-Agamy
et al., 2016; Cabot et al., 2011). The existence of three genetic
determinants of carbapenem resistance in a given isolate increased
MIC of imipenem above 16 mg/mL.
Interestingly, in isolates AH10 and RH35, MIC of meropenem
was above 16 mg/mL, although MexB overexpression was not
detectable, while for strains AH2, AH12, DH15, DH17, and DH29,
MIC of imipenem was above 16 mg/mL, although OprD downregulation was not detectable. In these 7 strains, we did not detect
carbapenemases. The patterns observed in these speciﬁc isolates
do not conform with generally recognized patterns of resistance.
This could be due to involvement of other factors like other efﬂux
pumps or carbapenemases not tested in our experiments, but
reported elsewhere (El Amin et al., 2005).
Our ﬁndings represent an addition to the global evidence
indicating versatility and diversity of resistance mechanisms in
this organism to carbapenems, with metallo-β-lactamases, permeability defects, and drug efﬂux, the latter two mechanisms
being nontransferable. Further assessment is needed to scrutinize
a probable role of certain Ambler class D enzymes and
chromosomally encoded AmpC-type β-lactamases in emergence
of such resistance (Potron et al., 2015).
The results of ﬁngerprinting by ERIC-PCR suggest that most
isolates (81%) probably originate from one clone disseminated in
all four hospitals. With one exception, this clone included all VIMproducing isolates. With blaVIM known to exist on a highly mobile
genetic environment on class 1 integrons, transposons, and
plasmids (Zhao and Hu, 2011), containment of such spread is
needed. A horizontal spread of carbapenem-nonsusceptible P.
aeruginosa in Dubai hospitals is suggested by the single VIMproducing isolate in clone 7. Many patients from whom samples
were recovered had chronic illness, severe infections or cancer, and
some had undergone invasive surgical procedures. A further
understanding of clinical data would have been useful to comment
on the clonality of the strains.
In conclusion, apparent mechanisms of carbapenem resistance
in P. aeruginosa from Dubai are VIM and GES carbapenemases
coupled with porin downregulation and efﬂux upregulation. With
such scenario, and given the particular multicultural aspects of this
geographic area, together with overwhelming resistance potential
in P. aeruginosa, Dubai remains a hot spot for interesting
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exploration in this ﬁeld. Continuous epidemiologic and mechanistic surveillance would lead to further evidence on such baseline
data and clarify carbapenem resistance in isolates that were
negative to investigated mechanisms in this study.
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